Currently authorised vaccines continue to be effective at preventing hospitalisation, severe disease and death due to #COVID19.
However, protection against the virus declines over time as new #SARSCoV2 variants emerge.
In line with the outcome of recent meetings of international regulators and the @WHO, @EMA_News Emergency Task Force recommends updating vaccines to target #XBB strains (a subgroup of #Omicron), which have become dominant in Europe and other parts of the world.
Both agencies (@ECDC_EU & @EMA_News) note that monovalent vaccines (vaccines targeting only one strain such as XBB.1.5) are a reasonable choice to provide protection against current dominant and emerging strains.
Timely vaccination ahead of a potential autumn and winter 2023 surge of #COVID19 cases is essential for protecting people from severe COVID-19 and health systems from being overwhelmed.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Mathematical modelling indicates that #XBB15 could become dominant in the EU/EEA after 1-2 months, given the current low proportions reported in the EU/EEA & its estimated growth rate.
No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.
The proportion of XBB.1.5 in EU/EEA was lower than 2.5% for the final 2 weeks of '22 (the most recent period where variant proportions at this low level can be accurately estimated).
In the US, #XBB15 is currently spreading 12% faster than other variants. bit.ly/XBB15TAB
A number of European countries (IE, FR, NL, ES, SE and UK) indicate an increase seen during 2022, particularly since September, in the number of cases of invasive Group A Streptococcus (#iGAS) disease among children less than ten years of age.
During the same period, several deaths associated with #iGAS in children less than 10 years of age have also been reported. The increase has been several-fold higher than pre-pandemic levels for the equivalent period of time.
Vaccines are continuing to prevent many millions of EU citizens from becoming very ill or dying and figures show that numbers of hospitalisations and deaths remain lowest in those Member States with the highest vaccination rates.
Due to a raise in #COVID19 infections and hospitalisations, we urge all EU citizens to get fully vaccinated and to adhere to recent recommendations on booster vaccination for #COVID19.
Recommendations on booster doses in our latest Rapid Risk Assessment: bit.ly/RRACOVID17
Providing all eligible individuals with the recommended dose regimen should remain the current
priority for #COVID19 vaccination programmes in the EU/EEA.
All vaccines authorised in the EU/EEA are highly protective against COVID19 related hospitalisation, severe disease & death.
Administering an additional vaccine dose to people who may experience a limited response to the primary #COVID19 vaccination, such as some categories
of immunocompromised individuals, should already be considered now.
With the increasing circulation of the #DeltaVariant in EU/EEA, #EMA & #ECDC strongly encourage those who are eligible for vaccination but have not yet been vaccinated to start and complete the recommended #COVID19 vaccination schedule soon.
Full vaccination with any of the approved vaccines = a high level of protection against severe disease and death.
The highest level of protection is achieved after enough time (7-14 days) after the last dose.